BR112023023506A2 - Composições incluindo intensificadores de terapia conjugada - Google Patents
Composições incluindo intensificadores de terapia conjugadaInfo
- Publication number
- BR112023023506A2 BR112023023506A2 BR112023023506A BR112023023506A BR112023023506A2 BR 112023023506 A2 BR112023023506 A2 BR 112023023506A2 BR 112023023506 A BR112023023506 A BR 112023023506A BR 112023023506 A BR112023023506 A BR 112023023506A BR 112023023506 A2 BR112023023506 A2 BR 112023023506A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions including
- intensifyers
- therapy
- including conjugation
- moiety
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000021615 conjugation Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
composições incluindo intensificadores de terapia conjugada. .a presente invenção refere-se a uma composição incluindo um primeiro composto tendo a estrutura p-n-lpm-moi, em que p-n é uma porção de agente proteico compreendendo um resíduo de lisina, lpm é um ligante e moi é uma porção de interesse e um segundo composto tendo a estrutura lg-oh, em que lg é um grupo compreendendo uma porção de ligação ao alvo que se liga a um agente alvo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163189503P | 2021-05-17 | 2021-05-17 | |
PCT/US2022/029533 WO2022245757A1 (en) | 2021-05-17 | 2022-05-17 | Compositions including conjugated therapy enhancers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023023506A2 true BR112023023506A2 (pt) | 2024-01-30 |
Family
ID=84140038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023023506A BR112023023506A2 (pt) | 2021-05-17 | 2022-05-17 | Composições incluindo intensificadores de terapia conjugada |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4351658A1 (pt) |
JP (1) | JP2024519031A (pt) |
KR (1) | KR20240012376A (pt) |
CN (1) | CN117295527A (pt) |
AU (1) | AU2022277840A1 (pt) |
BR (1) | BR112023023506A2 (pt) |
CA (1) | CA3219475A1 (pt) |
IL (1) | IL307746A (pt) |
MX (1) | MX2023013274A (pt) |
WO (1) | WO2022245757A1 (pt) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111148527A (zh) * | 2017-07-26 | 2020-05-12 | 克莱奥药品有限公司 | 通用abt化合物及其用途 |
WO2019241609A1 (en) * | 2018-06-15 | 2019-12-19 | Trustees Of Boston University | Polypeptide compositions and methods for site-specific targeting of therapeutic agents |
-
2022
- 2022-05-17 EP EP22805273.4A patent/EP4351658A1/en active Pending
- 2022-05-17 CN CN202280034211.XA patent/CN117295527A/zh active Pending
- 2022-05-17 JP JP2023571272A patent/JP2024519031A/ja active Pending
- 2022-05-17 BR BR112023023506A patent/BR112023023506A2/pt unknown
- 2022-05-17 CA CA3219475A patent/CA3219475A1/en active Pending
- 2022-05-17 IL IL307746A patent/IL307746A/en unknown
- 2022-05-17 WO PCT/US2022/029533 patent/WO2022245757A1/en active Application Filing
- 2022-05-17 MX MX2023013274A patent/MX2023013274A/es unknown
- 2022-05-17 KR KR1020237039153A patent/KR20240012376A/ko unknown
- 2022-05-17 AU AU2022277840A patent/AU2022277840A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022277840A1 (en) | 2023-11-30 |
WO2022245757A1 (en) | 2022-11-24 |
CA3219475A1 (en) | 2022-11-24 |
IL307746A (en) | 2023-12-01 |
JP2024519031A (ja) | 2024-05-08 |
AU2022277840A9 (en) | 2023-12-14 |
MX2023013274A (es) | 2023-11-30 |
CN117295527A (zh) | 2023-12-26 |
KR20240012376A (ko) | 2024-01-29 |
EP4351658A1 (en) | 2024-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012006686B8 (pt) | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa | |
BR112017017529A2 (pt) | derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo | |
BR112021026009A2 (pt) | Composições líquida e farmacêutica, conjugados dos análogos de tubulisina, análogo de tubulisina, agentes de ligação celular e sinérgico, e, célula tumoral | |
BR112017009601B8 (pt) | Derivados de aminoácidos e composição que os compreende | |
BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
MA31496B1 (fr) | Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c | |
MA29746B1 (fr) | Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c | |
BR112022017136A2 (pt) | Conjugação mediada por transglutaminase | |
BR112022009942A2 (pt) | Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado | |
BR112022016412A2 (pt) | Composições e método de deslignificação de biomassa vegetal ou material de biomassa | |
BR112014003981A2 (pt) | compostos de pirimido-piridazinona e seu uso | |
BR112021019957A2 (pt) | Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma | |
BR112023023506A2 (pt) | Composições incluindo intensificadores de terapia conjugada | |
BR112023006312A2 (pt) | Composto, métodos para preparar o composto, composição farmacêutica e uso do composto | |
BR112022003046A2 (pt) | Conjugados de il-15 e usos dos mesmos | |
CL2023001747A1 (es) | Composición farmacéutica de agonistas duales de glp-1/glp-2 | |
CL2023001745A1 (es) | Composición farmacéutica de agonistas duales de glp-1/glp-2 | |
CL2023002775A1 (es) | Conjugados de amatoxina y anticuerpo específicos de linfocitos b | |
CO2023010985A2 (es) | Composiciones adhesivas que comprenden adhesivos de base biológica a partir de recursos renovables, y su uso para la fabricación de madera contrachapada | |
BR112021021728A2 (pt) | Conjugado de anticorpo anti-bcma, composições que compreendem os mesmos e métodos para fazer e usar os mesmos | |
EP4331686A3 (fr) | Compositions à base d`alcanes et d`ester stables au stockage en température, leur utilisation comme agents émollients et émulsions les comprenant | |
BR112017027361A2 (pt) | agente para suprimir odores de compostos polissulfetados | |
BR112023026272A2 (pt) | Combinação, composição farmacêutica, e, kit de partes | |
AR123569A1 (es) | Conjugados de pirrolobenzodiazepina-anticuerpo y usos de los mismos | |
BR112023023951A2 (pt) | Compostos espiroindolinona como bloqueadores de canais shaker kv1.3 de potássio |